New Clinical Studies Demonstrate Efficacy of ElleVet Sciences’ CBD + CBDA for Expanded List of Pet Health Conditions

ElleVet Sciences, a leader in CBD + CBDA for pets, announced that recent clinical studies show its products to be efficacious for an expanded number of pet health conditions. While starting with studies proving efficacy for mobility in dogs, ElleVet has since furthered its investment in clinical research and simultaneously supported the health of hundreds of thousands of pets, demonstrating efficacy for mobility, stress, skin, neuro and cognitive support.

Reflecting the new findings, ElleVet’s packaging now includes condition-specific administration instructions to better assist veterinarians and pet parents in addressing specific health conditions using ElleVet’s CBD + CBDA products.

“Our dedication to scientific innovation has been ElleVet’s driving force and our ability to address an expanded number of health conditions demonstrates our commitment to furthering research for the benefit of dogs, cats and other species,” said Christian Kjaer, CEO and Co-Founder of ElleVet Sciences.

ElleVet is renowned for its pursuit of science addressing CBD + CBDA products for pets, as demonstrated through 15 peer-reviewed studies, 40 completed or in-progress R&D projects and a proven track record of improving the lives of dogs and cats.

As part of this announcement, ElleVet is also introducing a reformulated Feline Paste and a new 28mg soft gel option for dogs.

Aside from the feline paste, ElleVet’s product formulations have not changed. They are still the same safe and effective complete spectrum CBD + CBDA chews, soft gels and oils veterinary professionals and pet parents have grown to rely on.